Michael Yan, MD MPH
@MichaelYanMD
Followers
394
Following
1K
Media
12
Statuses
248
🇨🇦 |Radiation Oncologist @RadMedPM @PMcancercentre @UofTdro | Alumnus @Sunnybrook @QueensOncology @JohnsHopkinsSPH @SchulichMedDent | Views = mine
Toronto, Ontario
Joined January 2012
Our meta-analysis on the impact of biologically effective dose and dose-rate in #GammaKnife radiosurgery in trigeminal neuralgia is in @Advances_ASTRO! @MichaelYanMD @detsang @UofTDRO
We use some 👻🎃scary high🧙♀️☠️radiation doses when treating trigeminal neuralgia (TN) to reduce those pain ⚡️jolts! @janeJomy & team conducted this systemic review and meta-analysis of 8 publications including close to 2,600 patients! They found: ✅higher dose rate➡️higher pain
0
3
4
Psuedoprogression Radiation Necrosis vs progression new imaging techniques treating Rad Nec using Boswellia CNS PRO session #ASTRO25
2
27
81
1/ 🧵 Thrilled to share that our manuscript on immune modulation during curative RT is now published in the Red Journal! https://t.co/34T1BZYSE4 Here’s what we found about how RT reshapes systemic immunity (and why it may matter for distant mets)
2
9
22
Celiac plexus SRS for pancreatic cancer pain. Thank you to all my co-authors for the support with publishing this review @MichaelYanMD @LawrenceYaacov @ldawsonmd
https://t.co/FXy2BXTIBJ
0
4
11
I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️
19
86
319
🚨📢🌟 CURB2 Ph3 Trial is activated by @NCICTEP_ClinRes (NCT06686771), built upon CURB Ph2 RCT @TheLancet/@MSKCancerCenter. Appreciate the support of @NRGonc/@SWOG/@CCTG. Pls contact us for activation at your local site❗️ @pmcancercentre @ldawsonmd @DrAlexLouie @HoudaBahig
4
20
72
🚨NEW in @CACancerJournal: A comprehensive review of advances in hepatocellular carcinoma (#HCC) therapy. From surgery to IR to SBRT to immunotherapy, this is your clinical update 🧵 @NiuSanford @nbn426 @KrishanJethwa @safaviaa @ldawsonmd @aallam_mo @freddyeescorcia @5_utr
Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians @CACancerJournal @michael_lidsky
3
18
35
🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, @NRGonc for supporting our work! https://t.co/mGQBZOxjxJ 🙏🙏🙏
11
43
124
How to select pts with HCC for various local therapies? RFA ,MWA , TACE , SIRT , SBRT . Useful for clinical decision-making. Taken from #asco25 @ASCO Do u agree ? @dr_yakupergun @NiuSanford @jryckman3 @OncoAlert @medicalwatchBC
13
97
241
All You Need to Know: ASCO 🤝 Google Gemini 🧵 A quick breakdown of this bold move to bring AI into evidence-based oncology care — and what it means for the future. Let’s go: #AI #ASCO25 #DigitalHealth
@ASCO @ASCOPost @Google @jrgralow @GlopesMd @PatelOncology
1
11
20
🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No
4
76
171
“Skimming the median” – when winning arm hovers over median OS for long period, comparing median OS b/w groups results in exaggerated perceived benefit. ESOPEC given as ex, & I agree. FLOT outperformed CROSS, but stating FLOT extends OS by 29 mo is misleading. Great viewpoint!
13
30
112
Yesterday we treated our first patient on the Ph3 #ULTRAS trial—on board within 1 week of activation! Single-fraction SABR to liver mets from ENTSCC, NSCLC, CervSCC, and gastric/pancreatic ADC. @utswcancer @UTSW_RadOnc @Dr_AliHosni Excited to team up w/ partners and move fast!
0
5
17
Stellar job by @ldawsonmd in arguing that dose accumulation matters at #ESTRO25!! 👏👏👏 It certainly does if we want to further improve efficacy, reduce toxicity, and expand indications for #radonc 💪😊
2
8
23
🔬 New in The Green Journal: RTQA matters. This first meta-analysis links radiotherapy protocol deviations to worse survival in cancer trials. OS HR=1.65, PFS HR=1.79. Real-time QA could improve outcomes https://t.co/fOMxTcIBwc
#RTQA #Oncology #RadOnc
1
15
31
Congrats @TimothyJBrownMD! In this retrospective study, the addition of RT to atezo/bev added no measurable toxicity & was associated w improved RR (73% v 18%) & median OS (14.4 v 10.8 mo). Look forward to NRG GI-012, a Ph III trial assessing IO +/- SBRT for advanced HCC w MVI.
Excited to share our recent article "Evaluating the Safety and Efficacy of Adding Liver-Directed Radiation Therapy to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma A Single-Center Retrospective Cohort Analysis" out now in AJCO https://t.co/sqEuBee8Y8
0
19
47
🚨CAO/ARO/AIO-12 + OPRA Rectal trials🚨 WW vs. Planned surgery after TNT for rectal Ca 🟰 OS, DFS, DM ‼️Comparable outcomes when matched for response (cCR vs. pCR, etc) 🙌Supports WW as a highly appropriate, pt-centric, option for patients with cCR after TNT
1
48
93
1) After two years of mentoring UBC student Aiden under the supervision of Rob Olson and Sarah Baker at BC Cancer, our project is finally out in @IJROBP ! https://t.co/zQjsdM2mwc
3
12
36